On November 2023, the United States Food and Drug Administration (FDA) has approved Eli Lilly and Company s Zepbound (tirzepatide) injection, the first and only obesity medication to activate both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) hormone receptors
Using the wrong diluent, incorrect volume, or inappropriate technique can result in: Loss of potency the active compound degrades before administration Particulate formation aggregated peptide particles that may cause injection-site reactions or systemic effects Microbial contamination particularly when aseptic technique is not followed Inaccurate dosing leading to either sub-therapeutic or potentially toxic concentrations For licensed peptide medicines, manufacturers provide detailed, validated reconstitution instructions within the Summary of Product Characteristics (SmPC), reviewed and approved by regulators following rigorous stability testing
The combination is generally well tolerated, especially when monitored and started gradually
Treatment groups were compared with an ad libitum vehiclefed group and a weight-matched control group, to differentiate between the effects of weight loss induced by food restriction and GLP-1RA treatment (Supplemental Figure 10A)
Drug interactions with these medications is especially concerning, since most of them are used to treat life-threatening conditions
A 99% COA proves the product is safe. Chromatographic purity can support one part of chemical assessment
